Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Emraclidine
Другие языки:

    Emraclidine

    Подписчиков: 0, рейтинг: 0
    Emraclidine
    Emraclidine.svg
    Identifiers
    • 1-(2,4-dimethyl-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)-2-[1-[2-(trifluoromethyl)pyridin-4-yl]azetidin-3-yl]ethanone
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C20H21F3N4O
    Molar mass 390.410 g·mol−1
    3D model (JSmol)
    • CC1=CC(=NC2=C1CN(C2)C(=O)CC3CN(C3)C4=CC(=NC=C4)C(F)(F)F)C
    • InChI=1S/C20H21F3N4O/c1-12-5-13(2)25-17-11-27(10-16(12)17)19(28)6-14-8-26(9-14)15-3-4-24-18(7-15)20(21,22)23/h3-5,7,14H,6,8-11H2,1-2H3
    • Key:DTCZNKWBDTXEBS-UHFFFAOYSA-N

    Emraclidine (developmental code name CVL-231) is an investigational antipsychotic for the treatment of both schizophrenia and Alzheimer’s disease psychosis developed by Cerevel Therapeutics. As of February 2023, it is in phase II of clinical trial. Emraclidine is a positive allosteric modulator that selectively targets the muscarinic acetylcholine receptor M4 subtype. The M4 receptor subtype is expressed in the striatum of the brain, which plays a key role in regulating acetylcholine and dopamine levels. An imbalance of these neurotransmitters has been linked to psychotic symptoms in schizophrenia. Unlike other muscarinic receptors, M4 receptor subtypes are selectively expressed in the striatum and activation of these receptors has been shown to indirectly regulate dopamine levels without blocking D2/D3 receptors, which may lead to unwanted motor side effects seen in current antipsychotics.


    Новое сообщение